Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced that Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will present a corporate overview at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021 at 9:20 a.m. ET.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will present a corporate overview at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021 at 9:20 a.m. ET.
About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse kidney disease patient populations to identify subsets most likely to respond to our treatments. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies. Visit us at www.goldfinchbio.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005050/en/
Goldfinch Bio Contacts:
Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media:
Liz Melone
lmelone@goldfinchbio.com
Source: Goldfinch Bio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210614005050/en
